兴齐眼药(300573) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥403,699,656.59, representing a 31.08% increase compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2022 was ¥82,205,026.83, an increase of 8.26% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥78,505,975.55, up 7.48% from the previous year[4]. - The company's basic earnings per share for Q3 2022 were ¥0.93, reflecting a 1.09% increase year-on-year[4]. - Total operating revenue for the period reached CNY 1,004,272,176.87, a 30.2% increase from CNY 770,346,983.57 in the previous period[29]. - Net profit attributable to shareholders of the parent company was CNY 202,837,956.65, compared to CNY 156,074,589.73 in the same period last year, reflecting a 29.9% increase[30]. - Basic earnings per share increased to CNY 2.30 from CNY 1.90, representing a 21.1% growth[31]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥258,481,192.79, a 38.09% increase compared to the same period last year[11]. - The net cash flow from operating activities for Q3 2022 was ¥258,481,192.79, an increase from ¥187,183,581.68 in Q3 2021, representing a growth of approximately 38%[33]. - Total cash outflow from operating activities amounted to ¥743,279,515.56, compared to ¥560,355,964.56 in the same period last year, indicating a rise of about 32.5%[33]. - The net cash flow from investing activities was -¥242,106,777.66, a significant increase in outflow compared to -¥30,893,551.13 in Q3 2021[33]. - Cash inflow from financing activities was ¥20,000,000.00, down from ¥101,200,000.00 in Q3 2021, reflecting a decrease of approximately 80.3%[33]. - The total cash outflow from financing activities was ¥206,731,168.79, compared to ¥131,436,597.75 in the previous year, marking an increase of about 57%[33]. - The net increase in cash and cash equivalents was -¥170,382,111.77, contrasting with an increase of ¥125,954,296.02 in Q3 2021[33]. - The ending balance of cash and cash equivalents was ¥509,778,164.37, compared to ¥163,173,139.35 at the end of Q3 2021, showing a significant increase[33]. Assets and Liabilities - The total assets at the end of Q3 2022 were ¥1,771,030,391.59, reflecting a 4.99% increase from the end of the previous year[4]. - Total current assets decreased from CNY 984.42 million to CNY 892.74 million, a decline of approximately 9.3%[26]. - Total assets increased from CNY 1.69 billion to CNY 1.77 billion, reflecting a growth of about 5.1%[27]. - The total liabilities decreased to CNY 269,849,358.43 from CNY 342,351,345.70, a reduction of 21.2%[30]. - The total equity attributable to shareholders of the parent company increased to CNY 1,501,181,033.16 from CNY 1,344,492,935.02, reflecting a growth of 11.6%[30]. Expenses - Research and development expenses for Q3 2022 amounted to ¥90,447,355.09, a 45.26% increase year-on-year, indicating increased investment in R&D[9]. - The company reported a significant increase in sales expenses, totaling ¥342,715,262.71, which is a 36.98% rise compared to the previous year[9]. - Total operating costs amounted to CNY 759,480,791.26, up 31.0% from CNY 579,705,999.57 year-on-year[30]. - The company paid ¥267,379,097.90 in employee compensation, up from ¥196,680,210.52 in the same quarter last year, representing an increase of approximately 36%[33]. - Tax payments totaled ¥110,263,063.76, compared to ¥68,634,467.34 in Q3 2021, indicating a rise of about 60.5%[33]. - The company reported cash outflows related to other operating activities of ¥265,485,835.83, an increase from ¥214,356,982.03 in the previous year, reflecting a growth of approximately 23.9%[33]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,572, with the largest shareholder, Liu Jidong, holding 28.58% of the shares[12]. - The top ten shareholders collectively hold 25,175,500 shares, with the second-largest shareholder being the Fortune Tianhui Selected Growth Mixed Securities Investment Fund, holding 4.22%[12]. - Liu Jidong has 18,881,625 restricted shares, which are subject to a 25% annual unlock[14]. - Liu Jidong's shares are pledged, with 3,530,000 shares under pledge status[12]. - The company has not disclosed any relationships or concerted actions among the top ten shareholders[15]. - The company has not identified any financing or margin trading activities among the top ten common shareholders[15]. - The total number of restricted shares at the beginning of the period was 20,411,325, with 9,167 shares added during the period[15]. Corporate Governance - The company appointed Li Chunhua as a non-independent director following the resignation of Liu Gaozhi[18]. - The company appointed Gao E as the new General Manager, succeeding Liu Jidong, who remains as Chairman[19]. Regulatory and Project Updates - The company received approval for the Moxifloxacin Hydrochloride Eye Drops, with the drug approval number H20227050[21]. - The company signed a project investment agreement with the Shenyang Free Trade Zone Management Committee[22]. - The company approved the unlocking of 709,800 shares under the 2018 restricted stock incentive plan for 46 participants[23]. - The company approved the vesting of 460,400 shares under the 2021 restricted stock incentive plan for 91 participants[24]. - The company was re-certified as a high-tech enterprise, allowing it to enjoy a 15% corporate income tax rate for three years[25]. Liabilities and Financial Obligations - The company experienced a 77.81% increase in current non-current liabilities due to an increase in lease liabilities[8]. - The company reported a short-term loan of CNY 100 million from the central bank[27]. - Accounts payable decreased from CNY 13.31 million to CNY 10.95 million, a reduction of approximately 17.7%[27].